Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE)

doi 10.20944/preprints202003.0138.v1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Summary Report: Workshop on the Potential Risks of Antibody-Dependent Enhancement in Human HIV Vaccine Trials

AIDS Research and Human Retroviruses
VirologyInfectious DiseasesImmunology
1993English

Absence of Antibody-Dependent Enhancement (ADE) of Viral Infectivity in the Epidemic Neuropathy in Cuba

Memorias do Instituto Oswaldo Cruz
MedicineMicrobiology
1995English

2019-nCoV – Towards a 4th Generation Vaccine

Bioinformation
2020English

T Cell Epitope-Based Vaccine Design for Pandemic Novel Coronavirus 2019-nCoV

2020English

A Conceptual Model for Optimizing Vaccine Coverage to Reduce Vector-Borne Infections in the Presence of Antibody-Dependent Enhancement

Theoretical Biology and Medical Modelling
MedicineModelingSimulationHealth Informatics
2018English

D3Targets-2019-nCoV: A Web Server to Identify Potential Targets for Antivirals Against 2019-nCoV

2020English

Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV)

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2020English

Analysis of the Risks and Countermeasures of Enterprise Employee Recruitment

2018English

Wuhan 2019 Novel Coronavirus - 2019-nCoV

Materials and Methods
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy